Adherex to Present ADH-1 Phase I/II Melanoma Trial Data at the 2008 Annual Meeting of the American Society Of Clinical Oncology
20 Marzo 2008 - 1:30PM
Marketwired
RESEARCH TRIANGLE PARK, NORTH CAROLINA (AMEX: ADH), a
biopharmaceutical company with a broad portfolio of oncology
products under development, today announced that Phase I and
initial Phase II data from the Company's Phase I/II study of
systemic ADH-1 in combination with regional melphalan in melanoma
has been accepted for presentation at the 2008 American Society of
Clinical Oncology (ASCO) Annual Meeting, which takes place May 30 -
June 3, 2008 in Chicago, IL.
The poster presentation entitled "A phase I/II study of systemic
ADH-1 in combination with isolated limb infusion with melphalan
(ILI-M) in patients with locally advanced in-transit melanoma" is
scheduled to be presented on June 1, 2008 with a poster discussion
occurring between 5 and 6 pm.
Adherex is evaluating systemic ADH-1 in combination with
regional melphalan for the treatment of melanoma in an ongoing
multi-institutional Phase I/II trial which is expected to complete
patient accruals by approximately mid-2008. Participating centers
include Duke University Medical Center, MD Anderson Cancer Center,
Lehigh Valley Hospital and H. Lee Moffitt Cancer Center. The trial
has accrued 27 patients to date and patients with follow-up of
three months or more will be presented at ASCO.
About Adherex Technologies
Adherex Technologies Inc. is a biopharmaceutical company
dedicated to the discovery and development of novel cancer
therapeutics. We aim to be a leader in developing innovative
treatments that address important unmet medical needs in cancer. We
currently have multiple products in the clinical stage of
development, including eniluracil, ADH-1 and sodium thiosulfate
(STS). Eniluracil, an oral dihydropyrimidine dehydrogenase (DPD)
inhibitor, was previously under development by GlaxoSmithKline for
oncology indications. ADH-1, our lead biotechnology compound,
selectively targets N-cadherin, a protein present on certain tumor
cells and established blood vessels that feed solid tumors. STS, a
drug from our specialty pharmaceuticals pipeline, protects against
the disabling hearing loss that can often result from treatment
with platinum-based chemotherapy drugs. With a diversified
portfolio of unique preclinical and clinical-stage cancer compounds
and a management team with expertise in identifying, developing and
commercializing novel cancer therapeutics, Adherex is emerging as a
pioneering oncology company. For more information, please visit our
website at www.adherex.com.
This press release contains forward-looking statements that
involve significant risks and uncertainties. The actual results,
performance or achievements of the Company might differ materially
from the results, performance or achievements of the Company
expressed or implied by such forward-looking statements. Such
forward-looking statements include, without limitation, those
regarding the development plans of the Company and the expected
timing of our development. We can provide no assurance that such
development will proceed as currently anticipated or that the
expected timing of such development will be realized. We are
subject to various risks, including the uncertainties of clinical
trials, drug development and regulatory review, the early stage of
our product candidates, our reliance on collaborative partners, our
need for additional capital to fund our operations, our history of
losses, and other risks inherent to the biopharmaceutical industry.
For a more detailed discussion of related risk factors, please
refer to our public filings available at www.sedar.com and
www.sec.gov.
Contacts: Adherex Technologies Inc. D. Scott Murray Senior Vice
President, Corporate Development 919-484-8484 info@adherex.com
Grafico Azioni Adherex (AMEX:ADH)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Adherex (AMEX:ADH)
Storico
Da Mag 2023 a Mag 2024
